PHARMACOTHERAPEUTIC MONITORING FOR HIV PRE-EXPOSURE TREATMENT

Abstract

The Human Immunosuficiency Virus (HIV) is a serious worldwide problem. It infects the cells of the immune system, which can lead to the development of Acquired Immunodeficiency Syndrome (AIDS). Pre-exposure prophylaxis to HIV consists of using antiretrovirals before exposure to the HIV virus in order to reduce the risk of infection by it. Pharmacotherapeutic monitoring is defined as “a multidisciplinary clinical specialty that aims to improve patient care by individually adjusting the dose of medication. The aim of this article is to carry out an integrative review of the literature on the subject: pharmacotherapeutic monitoring for the treatment of pre-exposure to HIV. A bibliographic survey was carried out in the Scielo, LILACS, LA Referência and PubMed databases, from January 2013 to July 2023, in Portuguese, English and Spanish. The analysis of publications showed that vulnerability groups are composed of gay men and other men, transgender people, sex workers and serodiscordant people for HIV. The main laboratory evaluations that should be performed during the use of PrEp are: HIV test, syphilis test, identification of other STIs (chlamydia and gonococcus), hepatitis B test, hepatitis C test, monitoring of renal function , Creatinine clearance, urea and serum creatinine dosage, evaluation of proteinuria, monitoring of liver function (liver enzymes AST/ALT) and pregnancy test. The pharmacist's role in pharmacotherapeutic monitoring is based on the patient's clinical conditions. It is concluded that there is little information in the literature that addresses laboratory data and pharmacotherapeutic monitoring of patients who use PrEP during the period of drug treatment.